Deep molecular responses for treatment‐free remission in chronic myeloid leukemia

Por Dulucq, Stéphanie, Mahon, Francois‐Xavier
Publicado no Cancer Med (2016)

What is treatment free remission in chronic myeloid leukemia?

Por Rea, Delphine, Etienne, Gabriel, Mahon, François-Xavier
Publicado no Oncotarget (2017)

Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials

Por Tang, Min, Foo, Jasmine, Gönen, Mithat, Guilhot, Joëlle, Mahon, François-Xavier, Michor, Franziska
Publicado em 2012

A Single Nucleotide Polymorphism in cBIM Is Associated with a Slower Achievement of Major Molecular Response in Chronic Myeloid Leukaemia Treated with Imatinib

Por Augis, Vanessa, Airiau, Kelly, Josselin, Marina, Turcq, Béatrice, Mahon, François-Xavier, Belloc, Francis
Publicado em 2013

Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response

Por Legros, Laurence, Rousselot, Philippe, Giraudier, Stéphane, Tulliez, Michel, Huguet, Françoise, Nicolini, Franck-Emmanuel, Mahon, Francois-Xavier
Publicado em 2012

A tyrosine kinase-STAT5-miR21-PDCD4 regulatory axis in chronic and acute myeloid leukemia cells

Por Espadinha, Anne-Sophie, Prouzet-Mauléon, Valérie, Claverol, Stéphane, Lagarde, Valérie, Bonneu, Marc, Mahon, François-Xavier, Cardinaud, Bruno
Publicado no Oncotarget (2017)

Mycophenolic Acid Overcomes Imatinib and Nilotinib Resistance of Chronic Myeloid Leukemia Cells by Apoptosis or a Senescent-Like Cell Cycle Arrest

Por Drullion, Claire, Lagarde, Valérie, Gioia, Romain, Legembre, Patrick, Priault, Muriel, Cardinaud, Bruno, Lippert, Eric, Mahon, François-Xavier, Pasquet, Jean-Max
Publicado em 2012

Phosphorylation of Serine Palmitoyltransferase Long Chain-1 (SPTLC1) on Tyrosine 164 Inhibits Its Activity and Promotes Cell Survival

Por Taouji, Saïd, Higa, Arisa, Delom, Frédéric, Palcy, Sandrine, Mahon, François-Xavier, Pasquet, Jean-Max, Bossé, Roger, Ségui, Bruno, Chevet, Eric
Publicado em 2013

Expression of Neurotrophins and their Receptors in Human Bone Marrow

Por Labouyrie, Eric, Dubus, Pierre, Groppi, Alexis, Mahon, François Xavier, Ferrer, Jacky, Parrens, Marie, Reiffers, Josy, de Mascarel, Antoine, Merlio, Jean Philippe
Publicado em 1999

α-Defensin 1-3 And α-Defensin 4 as Predictive Markers of Imatinib Resistance and Relapse in CML Patients

Por Etienne, Gabriel, Dupouy, Maryse, Costaglioli, Patricia, Chollet, Claudine, Lagarde, Valérie, Pasquet, Jean-Max, Reiffers, Josy, Garbay, Bertrand, Mahon, François-Xavier, Turcq, Béatrice
Publicado em 2011

Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells

Por Airiau, Kelly, Prouzet-Mauléon, Valérie, Rousseau, Benoit, Pigneux, Arnaud, Jeanneteau, Marie, Giraudon, Manon, Allou, Kaoutar, Dubus, Pierre, Belloc, Francis, Mahon, François-Xavier
Publicado no Oncotarget (2015)

Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios

Por Saglio, Giuseppe, le Coutre, Philipp, Cortes, Jorge, Mayer, Jiří, Rowlings, Philip, Mahon, François-Xavier, Kroog, Glenn, Gooden, Kyna, Subar, Milayna, Shah, Neil P.
Publicado no Ann Hematol (2017)

The Necrotic Signal Induced by Mycophenolic Acid Overcomes Apoptosis-Resistance in Tumor Cells

Por Guidicelli, Gwendaline, Chaigne-Delalande, Benjamin, Dilhuydy, Marie-Sarah, Pinson, Benoît, Mahfouf, Walid, Pasquet, Jean-Max, Mahon, François-Xavier, Pourquier, Philippe, Moreau, Jean-François, Legembre, Patrick
Publicado em 2009

Variable Behavior of iPSCs Derived from CML Patients for Response to TKI and Hematopoietic Differentiation

Por Bedel, Aurélie, Pasquet, Jean- Max, Lippert, Éric, Taillepierre, Miguel, Lagarde, Valérie, Dabernat, Sandrine, Dubus, Pierre, Charaf, Lucie, Beliveau, François, de Verneuil, Hubert, Richard, Emmanuel, Mahon, François-Xavier, Moreau-Gaudry, François
Publicado em 2013

Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy

Por Lippert, Eric, Etienne, Gabriel, Mozziconacci, Marie-Joelle, Laibe, Sophy, Gervais, Carine, Girault, Stéphane, Gachard, Nathalie, Tigaud, Isabelle, Dastugue, Nicole, Huguet, François, Fort, Marie-Pierre, Legros, Laurence, Eclache, Virginie, Mahon, Francois-Xavier
Publicado em 2010

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy

Por Etienne, Gabriel, Dulucq, Stéphanie, Nicolini, Franck-Emmanuel, Morisset, Stéphane, Fort, Marie-Pierre, Schmitt, Anna, Etienne, Madeleine, Hayette, Sandrine, Lippert, Eric, Bureau, Caroline, Tigaud, Isabelle, Adiko, Didier, Marit, Gérald, Reiffers, Josy, Mahon, François-Xavier
Publicado em 2014

Chronic myeloid leukemia progenitor cells require autophagy when leaving hypoxia-induced quiescence

Por Ianniciello, Angela, Dumas, Pierre-Yves, Drullion, Claire, Guitart, Amélie, Villacreces, Arnaud, Peytour, Yan, Chevaleyre, Jean, Brunet de la Grange, Philippe, Vigon, Isabelle, Desplat, Vanessa, Priault, Muriel, Sbarba, Persio Dello, Ivanovic, Zoran, Mahon, François-Xavier, Pasquet, Jean-Max
Publicado no Oncotarget (2017)

Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients

Por Fossard, Gaëlle, Blond, Emilie, Balsat, Marie, Morisset, Stéphane, Giraudier, Stéphane, Escoffre-Barbe, Martine, Labussière-Wallet, Hélène, Heiblig, Maël, Bert, Arthur, Etienne, Madeleine, Drai, Jocelyne, Sobh, Mohamad, Redonnet-Vernhet, Isabelle, Lega, Jean-Christophe, Mahon, François-Xavier, Etienne, Gabriel, Nicolini, Franck Emmanuel
Publicado no Haematologica (2016)

Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study

Por Rousselot, Philippe, Prost, Stéphane, Guilhot, Joelle, Roy, Lydia, Etienne, Gabriel, Legros, Laurence, Charbonnier, Aude, Coiteux, Valérie, Cony‐Makhoul, Pascale, Huguet, Francoise, Cayssials, Emilie, Cayuela, Jean‐Michel, Relouzat, Francis, Delord, Marc, Bruzzoni‐Giovanelli, Heriberto, Morisset, Laure, Mahon, François‐Xavier, Guilhot, François, Leboulch, Philippe
Publicado no Cancer (2016)

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

Por Giles, Francis J., Abruzzese, Elisabetta, Rosti, Gianantonio, Kim, Dong-Wook, Bhatia, Ravi, Bosly, Andre, Goldberg, Stuart, Kam, Grace L.S., Jagasia, Madan, Mendrek, Wlodzimierz, Fischer, Thomas, Facon, Thierry, Dünzinger, Ulrich, Marin, David, Shou, Yaping, Gallagher, Neil J., Larson, Richard A., Mahon, Francois-Xavier, Baccarani, Michele, Cortes, Jorge, Kantarjian, Hagop M.
Publicado em 2010